Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence (2024)
Epidemiology and Psychiatric Sciences , Volume 33, 2024, e40 PMID: 39289881 DOI: 10.1017/S2045796024000441 Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence Published online by Cambridge University Press: 18 September 2024 David Healy (1), Dee Mangin (2,3) Affiliations (1) Data Based Medicine, Wales, UK. (2) Department of Family Medicine, McMaster University, Hamilton, ON, Canada. (3) Department of General Practice, University of Otago, Christchurch, New Zealand. Abstract While sexual dysfunction is a well-known side effect of taking selective serotonin reuptake inhibitors (SSRIs), in an undetermined number of patients, sexual function does not return to pre-drug baseline after stopping SSRIs. The condition is known as post-SSRI sexual dysfunction (PSSD) and is characterised most commonly by genital numbness, pleasureless or weak orgasm, loss of libido and erectile dysfunction. This article provides a commentary on the incidence and prevalence of PSSD base